Related Experiment Video
Updated: Mar 6, 2026
Fabrication of 3D Cardiac Microtissue Arrays using Human iPSC-Derived Cardiomyocytes, Cardiac Fibroblasts, and Endothelial Cells
Published on: March 14, 2021
3D Cardiac Constructs in Drug Discovery: Current Advances and Future Challenges.
Chang Liu1,2, Jing Guo1,2, Gunash Mirzayeva1,2
1Cardiac Regeneration and Ageing Lab, Institute of Geriatrics (Shanghai University), Affiliated Nantong Hospital of Shanghai University (The Sixth People's Hospital of Nantong) and School of Life Science, Shanghai University, Nantong 226011, China.
Three-dimensional (3D) cardiac constructs offer advanced preclinical models for studying cardiovascular diseases and accelerating drug discovery. This review highlights their technology, applications, and future potential in medicine.
Area of Science:
- Biomedical Engineering
- Cardiovascular Research
- Drug Discovery
Background:
- 3D cardiac constructs serve as advanced preclinical models for cardiovascular diseases.
- These models are crucial for understanding disease mechanisms and facilitating drug discovery.
- Recent technological advancements have enhanced the utility of these constructs.
Purpose of the Study:
- To review recent advancements in 3D cardiac construct technology.
- To explore the applications of 3D cardiac constructs in drug development.
- To discuss limitations and future directions in the field.
Main Methods:
- Review of recent literature on 3D cardiac constructs.
- Summarization of disease models, assessment parameters, and biomaterials.
- Discussion of drug screening, AI integration, and technical challenges.
Main Results:
- Identified key types of 3D cardiac disease models and assessment parameters.
- Highlighted the role of novel biomaterials and AI in advancing construct technology.
- Detailed progress in 3D cardiac construct-based drug screening.
Conclusions:
- 3D cardiac constructs are pivotal for preclinical cardiovascular research and drug discovery.
- Technological progress, including AI, enhances their predictive power.
- Addressing current limitations will further unlock their potential in therapeutic development.
